- Biotechnology
- Wednesday, 24 Jun 2020
Philogen Received Combination Pack Approval for Nidlegy
Philogen S.p.A., a privately-owned biotechnology company, is pleased to announce that, on Jan. 30, 2020, EMA's CHMP expressed a favorable opinion to the request of a combination pack for the to-be-marketed pharmaceutical form of NidlegyTM, a combination of the active principles bifikafusp alfa (L19IL2) and onfekafusp alfa (L19TNF). NidlegyTM is being developed as a neoadjuvant intralesional treatment for resectable Stage III melanoma patients and in locally advanced, not metastatic nonmelanoma skin cancers. NidlegyTM combination pack has now received confirmation of eligibility to the centralized procedure for submission of an application for a Union Marketing Authorisation under Article 3(1) - Indent 1 - Biotech medicinal product of Regulation (EC) No 726/2004.
"We are extremely pleased to record EMA's agreement to our strategy for the marketing of NidlegyTM as a combination pack that was considered by CHMP 'indispensable for public health reasons,'" commented Prof. Dario Neri, co-founder and President of the Scientific Advisory Board of Philogen.
Related Industry Updates
SFA Therapeutics Announces FDA Approval To Begin IND Trial
Jun 29, 2020
Higher Investment in R&D boost Pre Clinical CROs Market in Developed Countries
Apr 20, 2020
Oral Cancer Rapid Test Kit Market Repository of Analysis, Information for Every Facet of the Industry
Dec 10, 2020
Europe Immunochemistry Market Size Estimated to Observe Significant Growth by 2027
Jan 07, 2021
Digestive System Drugs Market – Know What Segments & Players Seeking Heavy Attention
Apr 26, 2021
Biological Data Visualization Market to Bolster the Growth during the Forecast Period 2021–2027 with Carl Zeiss AG, Oxford Instruments, BD, Genedata AG, OLYMPUS CORPORATION, Clarivate
Mar 17, 2021
Organ Preservation Solution Market is expected to reach US$ 399,497.49 million by 2028.
May 12, 2023
Follow us on
